Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for anthracycline-associated cardiotoxicity

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Carbonyl reductase (CBR) catalyzes anthracycline metabolism, and single nucleotide polymorphisms (SNPs) in CBR impact metabolic efficiency. In pediatric patients, homozygosity for the major allele (G) in the CBR3 gene was associated with increased risk of anthracycline cardiotoxicity. We hypothesized that CBR SNPs contribute to cardiotoxicity in adults.

Methods

We retrospectively identified female breast cancer patients in the Columbus Breast Tissue Bank Registry treated with adriamycin and cytoxan (AC) from 2003 to 2012. We selected patients who developed cardiomyopathy, defined as a drop in ejection fraction to <50 % or >15 % decrease from pre-therapy. Univariate and multivariate logistic regressions were performed to identify cardiotoxicity risk factors. SNPs were genotyped, and frequency of the major allele (G)/minor allele (A) of the CBR3 and CBR1 genes was calculated.

Results

We identified 52 cases of cardiotoxicity after AC and 110 controls. Multivariate analysis showed that trastuzumab (p = 0.009), diabetes (p = 0.05), and consumption of >8 alcoholic drinks/week (p = 0.024) were associated with higher cardiotoxicity risk. Moderate alcohol consumption (<8 drinks/week) was associated with lower risk (p = 0.009). No association was identified between CBR SNPs and cardiotoxicity (CBR1 p = 0.261; CBR3 p = 0.556).

Conclusions

This is the first study to evaluate SNPs in the CBR pathway as predictors of AC cardiotoxicity in adults. We did not observe any significant correlation between cardiotoxicity and SNPs within the CBR pathway. Further investigation into CBR SNPs in a larger adult sample is needed. Additional exploration into genomic predictors of anthracycline cardiotoxicity may allow for the development of preventative and therapeutic strategies for those at risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buzdar AU, Marcus C, Smith TL, Blumenschein GR (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55(12):2761–2765

    Article  CAS  PubMed  Google Scholar 

  2. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869–2879. doi:10.1002/cncr.11407

    Article  CAS  PubMed  Google Scholar 

  3. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900–905. doi:10.1056/NEJM199809243391307

    Article  CAS  PubMed  Google Scholar 

  4. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol: Off J Am Soc Clin Oncol 19(1):191–196

    Article  CAS  Google Scholar 

  5. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710–717

    Article  Google Scholar 

  6. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS (2004) Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the north central cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol: Off J Am Soc Clin Oncol 22(18):3700–3704. doi:10.1200/JCO.2004.03.516

    Article  CAS  Google Scholar 

  7. Rahman AM, Yusuf SW, Ewer MS (2007) Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2(4):567–583

    CAS  Google Scholar 

  8. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol: Off J Am Soc Clin Oncol 23(34):8597–8605. doi:10.1200/JCO.2005.02.5841

    Article  Google Scholar 

  9. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM (2010) Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 56(20):1644–1650. doi:10.1016/j.jacc.2010.07.023

    Article  PubMed  Google Scholar 

  10. Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Exp Rev Anticancer Ther 11(2):263–275. doi:10.1586/era.10.226

    Article  CAS  Google Scholar 

  11. Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7(10):564–575. doi:10.1038/nrcardio.2010.121

    Article  PubMed  Google Scholar 

  12. Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, Walker JR, Lister D, Arora RC, Barac I, Morris A, Jassal DS (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treatment 117(2):357–364. doi:10.1007/s10549-008-0260-6

    Article  CAS  Google Scholar 

  13. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4, CD006243. doi:10.1002/14651858.CD006243.pub2

    Google Scholar 

  14. Volkova M, Russell R 3rd (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7(4):214–220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100(5):684–692. doi:10.1038/sj.bjc.6604909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM (2012) Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 12:381. doi:10.1186/1471-2407-12-381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mushlin PS, Cusack BJ, Boucek RJ Jr, Andrejuk T, Li X, Olson RD (1993) Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110(3):975–982

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group. J Clin Oncol: Off J Am Soc Clin Oncol 30(13):1415–1421. doi:10.1200/JCO.2011.34.8987

    Article  CAS  Google Scholar 

  19. Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99(10):2045–2054. doi:10.1111/j.1349-7006.2008.00903.x

    CAS  PubMed  Google Scholar 

  20. Bonadonna G, Monfardini S (1969) Cardiac toxicity of daunorubicin. Lancet 1(7599):837

    Article  CAS  PubMed  Google Scholar 

  21. Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pages G, Milano G (2007) Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 18(8):1335–1341. doi:10.1093/annonc/mdm181

    Article  CAS  Google Scholar 

  22. Lemieux J, Diorio C, Cote MA, Provencher L, Barabe F, Jacob S, St-Pierre C, Demers E, Tremblay-Lemay R, Nadeau-Larochelle C, Michaud A, Laflamme C (2013) Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 33(6):2569–2576

    CAS  PubMed  Google Scholar 

  23. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G (2009) Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23(6):1118–1126. doi:10.1038/leu.2008.398

    Article  CAS  PubMed  Google Scholar 

  24. Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, Lautner-Csorba O, Szabolcs J, Masat P, Fekete G, Falus A, Szalai C, Kovacs GT (2012) ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int 36(1):79–86. doi:10.1042/CBI20110264

    Article  CAS  PubMed  Google Scholar 

  25. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24):3754–3762. doi:10.1161/CIRCULATIONAHA.105.576850

    Article  CAS  PubMed  Google Scholar 

  26. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety C, (2012) Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol: Off J Am Soc Clin Oncol 30(13):1422–1428. doi:10.1200/JCO.2010.34.3467

    Article  Google Scholar 

  27. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60(18):5158–5164

    CAS  PubMed  Google Scholar 

  28. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G (2013) Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 112(12):1980–1984. doi:10.1016/j.amjcard.2013.08.026

    Article  CAS  PubMed  Google Scholar 

  29. Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, Paton V, Holmgren E, Mahaffey KW (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol: Off J Am Soc Clin Oncol 28(21):3416–3421. doi:10.1200/JCO.2009.23.6950

    Article  CAS  Google Scholar 

  30. Piano MR (2002) Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 121(5):1638–1650

    Article  PubMed  Google Scholar 

  31. Obi N, Gornyk D, Heinz J, Vrieling A, Seibold P, Chang-Claude J, Flesch-Janys D (2014) Determinants of newly diagnosed comorbidities among breast cancer survivors. J Cancer Survivorship: Res Pract 8(3):384–393. doi:10.1007/s11764-013-0338-y

    Article  Google Scholar 

  32. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Res 10:5. doi:10.1186/1532-429X-10-5

    Article  Google Scholar 

  33. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A (2013) Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 99(9):634–639. doi:10.1136/heartjnl-2012-303151

    Article  CAS  PubMed  Google Scholar 

  34. Ezaz G, Long JB, Gross CP, Chen J (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1), e000472. doi:10.1161/JAHA.113.000472

    Article  PubMed  PubMed Central  Google Scholar 

  35. Walker JR, Singal PK, Jassal DS (2009) The art of healing broken hearts in breast cancer patients: trastuzumab and heart failure. Exp Clin Cardiol 14(3):e62–e67

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Zeglinski M, Ludke A, Jassal DS, Singal PK (2011) Trastuzumab-induced cardiac dysfunction: a 'dual-hit'. Exp Clin Cardiol 16(3):70–74

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105(13):1551–1554

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

None.

Author information

Authors and Affiliations

  1. The Breast Program, The Ohio State University Comprehensive Cancer Center and the Stefanie Spielman Comprehensive Breast Center, B421 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH, 43210, USA

    Raquel E. Reinbolt, Charles L. Shapiro & Maryam B. Lustberg

  2. The Ohio State University College of Medicine, 1470, Highland St., Columbus, OH, 43210, USA

    Roshan Patel

  3. Center for Biostatistics, The Ohio State University Comprehensive Cancer Center, 2012, Kenny Road, Columbus, OH, 43221, USA

    Xueliang Pan

  4. The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    Cynthia Dawn Timmers

  5. Division of Human Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    Robert Pilarski

Authors
  1. Raquel E. Reinbolt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roshan Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xueliang Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cynthia Dawn Timmers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Pilarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles L. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maryam B. Lustberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raquel E. Reinbolt.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Raquel E. Reinbolt and Roshan Patel contributed equally to first authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reinbolt, R.E., Patel, R., Pan, X. et al. Risk factors for anthracycline-associated cardiotoxicity. Support Care Cancer 24, 2173–2180 (2016). https://doi.org/10.1007/s00520-015-3008-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-3008-y

Keywords

Search

Navigation